Abstract
The immunosuppressant, SDZ IMM 125 (IMM), is a derivative of cyclosporin A (CyA). The disposition kinetics of IMM in plasma, blood cells, and various tissues of the rat was characterized by a physiologically based pharmacokinetic (PBPK) model; the model was then applied to predict the disposition kinetics in dog and human. Accumulation of IMM in blood cell is high (equilibrium blood cell/plasma ratio=8), although the kinetics of drug transference between plasma and blood cell is moderately slow, taking approximately 10 min to reach equilibrium, implying a membranelimited distribution into blood cells. A local PBPK model, assuming blood-flow limited distribution and tissue/blood partition coefficient (K P) data, failed to adequately describe the observed kinetics of distribution, which were slower than predicted. A membrane transport limitation is therefore needed to model dynamic tissue distribution data. Moreover, a slowly interacting intracellular pool was also necessary to adequately describe the kinetics of distribution in some organs. Three elimination pathways (metabolism, biliary secretion, and glomerular filtration) of IMM were assessed at steady statein vivo and characterized independently by the corresponding clearance terms. A whole-body PBPK model was developed according to these findings, which described closely the IMM concentration-time profiles in arterial blood as well as 14 organs/tissues of the rat after intravenous administration. The model was then scaled up to larger mammals by modifying physiological parameters, tissue distribution and elimination clearances;in vivo enzymatic activity was considered in the scale-up of metabolic clearance. The simulations agreed well with the experimental measurements in dog and human, despite the large interspecies difference in the metabolic clearance, which does not follow the usual allometric relationship. In addition, the nonlinear increase in maximum blood concentration andAUC with increasing dose, observed in healthy volunteers after intravenous administration, was accommodated quantitatively by incorporating the known saturation of specific binding of IMM to blood cells. Overall, the PBPK model provides a promising tool to quantitatively link preclinical and clinical data.
Similar content being viewed by others
References
A. Bernareggi and M. Rowland. Physiological modelling of cyclosporin kinetics in rats and man.J. Pharmacokin. Biopharm. 19:21–50 (1991).
R. Kawai and M. Lemaire. Role of blood cell uptake on cyclosporin pharmacokinetics.Proceeding of the International Symposium on Blood Binding and Drug Transfer, EFC Publishing, Paris, 1993, pp. 89–108.
P. C. Heistand, M. Graeber, U. Hurtenbach, P. Herrmann, S. Cammisuli, B. P. Richardson, M. K. Eberle, and J. F. Borel. The new cyclosporine derivative, SDZ IMM 125; in vitro and in vivo pharmacologic effects.Transplant Proc. 24:31–38 (1992).
A. Bruelisauer, R. Kawai, P. Misslin, and M. Lemaire. Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration.Drug Metab. Dispos. 22:194–199 (1994).
B. Legg and M. Rowland. Cyclosporin: erythrocyte binding and an examination of its use to estimate unbound concentration.Ther. Drug Monit. 10:16–19 (1988).
B. Foxwell, G. Frazer, M. Winters, P. Hiestand, R. Wenger, and B. Ryffel. Identification of cyclophilin as the erythrocyte cyclosporin-binding protein.Biochim. Biophys. Acta 938:447–455 (1988).
A. Tsuji, K. Nishide, H. Minami, E. Nakashima, T. Terasaki, and T. Yamana. Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man.Drug Metab. Dispos. 13:729–739 (1985).
C. Sloop, L. Dory, and P. Roheim. Interstitial fluid lipoproteins.J. Lipid Res. 28:225–237 (1987).
W. M. Pardridge, D. Triguero, J. Yang, and P. A. Cancilla. Comparison of in vitro and in vivo models of drug transcytosis through the blood brain barrier.J. Pharmacol. Exp. Ther. 253:884–891 (1990).
J. Fisher, T. Whittaker, D. Taylor, H. Clewell, and M. Anderson. Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure for trichloroethylene and its metabolite, trichloroacetic acid.Toxicol. Appl. Pharmacol. 99:395–414 (1989).
D. Staats, J. Fisher, and R. Connolly. Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic model; a two-compartment description.Drug Metab. Dispos. 19:144–148 (1991).
F. Ichimura, K. Yokogawa, T. Yamana, A. Tsuji, K. Yamamoto, S. Murakami, and Y. Mizukami. Physiological pharmacokinetic model for distribution and elimination of pentazocine. II. Study in rabbits and scale-up to man.Int. J. Pharm. 19:75–88 (1984).
S. Khor and M. Mayersohn. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling; Residual tissue blood. I. Theoretical considerations.Drug Metab. Dispos. 19:478–485 (1991).
S. Khor, H. Bozigian, and M. Mayersohn. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling; Residual tissue blood.II. Distribution of phencyclidine in the rat.Drug Metab. Dispos. 19:486–490 (1991).
P. Altman. Analysis and compilation. In D. Dittman (ed.),Biological Handbooks: Blood and Other Body Fluids FASEB, Washington, DC, 1961.
L. Jansky and J. Hart. Cardiac output and organ blood flow in warm-and cold-acclimated rats exposed to cold.Can. J. Physiol. Pharmacol. 46:653–659 (1968).
A. Tsuji, T. Yoshikawa, K. Nishide, H. Minami, M. Kimura, E. Nakashima, T. Terasaki, E. Miyamoto, C. Nightingale, and T. Yamana. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats.J. Pharm. Sci. 72:1239–1252 (1983).
A. Tsuji, H. Sato, I. Tamai, H. Adachi, T. Nishihara, M. Ishiguro, N. Ohnuma, and T. Noguchi. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.Drug Metab. Dispos. 18:245–252 (1990).
S. Pang and M. Rowland. Hepatic clearance of drugs.I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding and hepatocellular enzymatic activity on hepatic drug clearance.J. Pharmacokin. Biopharm. 5:625–653 (1977).
H. Akima. A new method of interpolation and smooth curve fitting based on local procedures,Journal of ACM 17:589–602 (1970).
H. Akaike. An information criterion (AIC).Math. Sci. 14: 5–9 (1976).
R. Dedrick, M. Flessner, J. Collins, and J. Schultz. Is the peritoneum a membrane?ASAIO Journal 51:1–8 (1982).
J. Holt and E. Rhode. Similarity of renal glomerular hemodynamics in mammals.Am. Heart J. 92:465–472 (1976).
A. Vickers, E. Meyer, R. Dannecker, B. Keller, R. Tynes, and G. Maurer. Human Liver Cytochrome P4503A Biotransformation of the Cyclosporin Derivative SD2IMM125.Drug Metab. Dispos. 23; 1–6 (1995).
A. Vickers, V. Fischer, S. Connors, R. Fisher, J-P. Baldeck, G. Maurer, and K. Brendel. Cyclosporin A metabolism in human liver, kidney, and intestine slices: Comparison to rat and dog slices and human cell lines.Drug Metab. Dispos. 20:802–809 (1992).
J. Mordenti and W. Chappell. The use of interspecies scaling in toxicokinetics. In A. Yacobi, J. Skelly, and V. Batra (eds.),Toxicokinetics and New Drug Development, Pergamon Press, New York, 1989, pp. 42–96.
S. Urien, R. Zini, M. Lemaire, and J-P. Tillement. Assessment of cyclosporine A interactions with human plasma lipoproteins in vitro and in vivo in the rat.J. Pharmacol. Exp. Ther. 253:305–309 (1990).
H. Lee and W. Chiou. Erythrocytes as barriers for drug elimination in the isolated rat liver.I. Doxorubicin.Pharm. Res. 6:833–839 (1989).
H. Lee and W. Chiou. Erythrocytes as barriers for drug elimination in the isolated rat liver.II. Propanol.Pharm. Res. 6:840–843 (1989).
T. Chen, M. Abdelhameed, and W. Chiou. Erythrocytes as a total barrier for renal excretion of hydrochlorothiazide: Slow influx and efflux across erythrocyte membranes.J. Pharm. Sci. 81:212–218 (1992).
R. Kawai, Y. Sawada, M. Channing, B. Dunn, A. Newman, K. Rice, and R. Blasberg. Kinetic analysis of the opiate antagonist cyclofoxy in rat brain: Simultaneous infusion of active and inactive enantiomers.J. Pharmacol. Exp. Ther. 255:826–835 (1990).
J. Gallo, P. Varkonyi, E. Hassan, and D. Groothius. Targeting anticancer drugs to the brain:II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats.J. Pharmacokin. Biopharm. 21:575–592 (1993).
T. Terasaki, T. Iga, Y. Sugiyama, and M. Hanano. Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: Interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits and guinea pigs.J. Pharm. Sci. 73:1359–1363 (1984).
M. Roberts and M. Rowland. A dispersion model of hepatic elimination:I. formulation of the model and bolus considerations.J. Pharmacokin. Biopharm. 14:227–260 (1986).
H. Sato, Y. Sugiyama, T. Iga, and M. Hanano. Physiologically based pharmacokinetics of radioiodinated human beta-endorphin in rats: an application of capillary membrane-limited model.Drug Metab. Dispos. 15:540–550 (1987).
L. Sangalli, A. Bortolotti, L. Jiritano, and M. Bonati. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, humans.Drug. Metab. Dispos. 16:749–753 (1988).
H. Boxenbaum. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics.J. Pharmacokin. Biopharm. 10:201–227 (1982).
R. Dedrick. Interspecies scaling of regional drug delivery.J. Pharm. Sci. 75:1047–1052 (1986).
J. L. Gabrielsson, P. Johansson, U. Bondesson, and L. K. Paalzow. Analysis of methadone disposition in the pregnant rat by means of a physiological flow model,J. Pharmacokin. Biopharm. 13:355–372 (1985).
E. Adolph. Quantitative relations in the physiological constitutions of mammals.Science 109:579–585 (1949).
H. Boxenbaum. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin,J. Pharmacokin. Biopharm. 8:165–176 (1980).
J. Katz, G. Bonorris, S. Golden, and A. Sellers. Extravascular albumin mass and exchange in rat tissues.Clin. Sci. 39:705–724 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawai, R., Lemaire, M., Steimer, JL. et al. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. Journal of Pharmacokinetics and Biopharmaceutics 22, 327–365 (1994). https://doi.org/10.1007/BF02353860
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02353860